Picture of AtriCure logo

ATRC AtriCure News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapFalling Star

AtriCure Inc expected to post a loss of 17 cents a share - Earnings Preview

* AtriCure Inc  ATRC.OQ   ATRC.O  is expected to show a rise
in
quarterly revenue when it reports  results on July 30 for the
period ending June 30 2024
    * The Mason Ohio-based  company is expected to report a
15.1% increase in revenue to $116.183 million from $100.92
million a year ago, according to the mean estimate from 9
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for AtriCure Inc is for a
loss
of 17 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for AtriCure
Inc is
$44.50​, above​ its last closing price of $22.10. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.22       -0.23      -0.28     Missed  -22.6
 Jan. 1 2024   -0.23       -0.23      -0.21     Beat    8.5
 Sep. 30 2023  -0.31       -0.31      -0.20     Beat    35.8​
 Jun. 30 2023  -0.29       -0.30      -0.11     Beat    62.8
 ​​Mar.        -0.34       -0.34      -0.23     Beat    32.1
 31 2023                                                
 Dec. 31 2022  -0.17                  -0.09             48.8​
 Sep. 30 2022  -0.25       -0.25      -0.27     Missed  -6.8
 Jun. 30 2022  -0.29       -0.29      -0.32     Missed  -9.3
 This summary was machine generated July 27 at 00:29 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on AtriCure

See all news